-
Five-year outlook: After the "three medical" data linkage, the national market will be unified and changed
Time of Update: 2022-01-09
, and unblock data sharing channels between departments, regions, and industries "Three-medicine linkage" big data application imagination and preparations for pharmaceutical companies Through the efforts of the "14th Five-Year Plan", the data of medical care, medical insurance and medicine has gradually improved standards and information processing specifications from decentralization and fragmentation, unified data structure and improvement of data transmission and storage.
-
Hit the first domestic RNA therapy!
Time of Update: 2022-01-09
According to the prospectus, about 243 million Hong Kong dollars from the IPO of Sinochem will be used to fund the development and commercialization of STP705; about 65.
-
2021 Global RNA Therapy Financing Top 10
Time of Update: 2022-01-09
Investment agency: Company official website: official website: PepGen is a biotechnology company based in Oxford, England, founded in 2018, focusing on the development of oligonucleotide therapies and their delivery technologies .
-
Sihuan Pharmaceutical acquires Genesis Biosystems of the United States to further expand the medical aesthetics pipeline
Time of Update: 2022-01-09
Founded in 2001, Genesis is a manufacturer of high-quality aesthetics and biomedical products, mainly engaged in the development, manufacturing and distribution of beauty equipment, focusing on microchannel systems and fat collection products for cosmetic skin care treatments and plastic surgery .
-
Novavax and SII are authorized for emergency use of vaccines in India
Time of Update: 2022-01-09
The Novavax/SII vaccine has recently received emergency use authorization (EUA) in Indonesia and the Philippines, and has been included in the World Health Organization (WHO) Emergency Use List (EUL) .
Novavax's vaccine has also received a conditional marketing authorization from the European Commission and is included in the WHO's Emergency Use List (EUL).
com/2021-12-28-Novavax-and-Serum-Institute-of-India-Receive-Emergency-Use-Authorization-for-COVID-19-Vaccine-in-Indiahttps://ir.
com/2021-12-28-Novavax-and-Serum-Institute-of-India-Receive-Emergency-Use-Authorization-for-COVID-19-Vaccine-in-India
-
A bold outlook for innovative drugs in 2022
Time of Update: 2022-01-09
The wealthy Big pahrma + small and medium-sized biomedical companies stock market crash ≈ the era of big mergers and acquisitions The epidemic has brought a lot of cash flow to Big pahrma, and the pattern has also changed to some extent.
-
Hu Shanlian: New Trends and Challenges in Global Pharmacoeconomics Research 2022
Time of Update: 2022-01-09
Emerging scientific frontiers and opportunities are driving the development of HTA (Health Technology Assessment) and HEOR (Health Economics and Outcomes Research), and the widespread application of real-world research methods will become a trend .
-
Top ten keywords of the biomedical industry in 2021
Time of Update: 2022-01-09
Head pharmaceutical companies such as Hengrui Pharmaceutical (HOT-Ig), BeiGene, and Hibody also began to build dual-antibody technology platforms Keyword 6: mRNAKeyword 6: mRNA In the new crown epidemic, mRNA therapy ushered in a historic development opportunity .
-
4 balloons for one operation after collection?
Time of Update: 2022-01-09
In this regard , the National Medical Insurance Bureau stated that in the centralized procurement work, it has always adhered to a "zero tolerance" attitude towards quality issues, and has adopted strict rules and system design to ensure the quality and safety of selected products .
-
Would it be an overkill for the pharmaceutical secondary market to "rising first and then suppressing"?
Time of Update: 2022-01-09
"In the past two years, it has gradually entered the era of innovative drugs where pharmacoeconomics is king", In the just-concluded 2021 medical insurance negotiations, many new products have entered the medical insurance catalog, and from the capital market feedback on the day of the negotiation, everyone is still looking forward to the 2021 medical insurance negotiations .
-
Up 2 places!
Time of Update: 2022-01-09
The overall output of China's outstanding scientific and technological papers continues to grow, and the number of international top journal papers ranks second in the world, an increase of 2 places; the number of highly cited papers and hot papers continues to rank second in the world .
-
Inventory of domestic ADC financing in 2021
Time of Update: 2022-01-09
The competition for new ADC drugs, CDMO, is also becoming increasingly fierce.
In any case, the extension of targeted conjugated drugs is very broad, and more new technologies are expected to break through the boundaries of traditional ADCs and benefit patients through clinical verification .
-
In December, 6 Class 1 new drugs and 2 first copy approvals were approved, and these 6 blockbuster varieties declared new indications
Time of Update: 2022-01-09
SummarySummary In December, CDE undertook 1,366 drug registration applications For the first time, 11 stock varieties have company declaration consistency evaluation 5 Class 1 new drugs are reported for production, and 6 blockbuster varieties have new applications for marketing In the imitation application, there are no domestically approved 24 varieties 6 Class 1 innovative drugs were approved, of which 3 were Class 1.
-
Domestic PD-(L)1 explodes in 2021, and imported drugs face extinction
Time of Update: 2022-01-09
In November of this year, Professor Lu Shun from the Thoracic Hospital of Shanghai Jiaotong University reported at the ESMO Asia conference the interim analysis results of the randomized, double-blind, multicenter phase III study ORIENT-31 (NCT03802240), showing that Sintilizumab is combined Bevacizumab biosimilars and chemotherapy for EGFR-positive locally advanced or metastatic non-squamous NSCLC patients who have progressed through EGFR-TKI treatment have obtained significant and clinically significant PFS prolongation .
-
CanSino Bio's tetravalent meningococcal conjugate vaccine is approved for marketing in China
Time of Update: 2022-01-09
Retrieved Dec 29, 2020, from https:// [2] CanSinoBio's first domestic tetravalent meningococcal conjugate vaccine new drug registration application has been given priority review.
com/s/Sg0-o1e0ctAgx8UVKgaevg[3]CanSinoBio and Pfizer signed a promotion service agreement for a tetravalent meningococcal conjugate vaccine that is expected to be approved.
-
The first release of the Chinese Academy of Sciences Xu Huaqiang/Yin Wanchao team to jointly tackle the new coronavirus Omicron mutant strain spike protein and its complex structure with receptors and antiviral antibodies
Time of Update: 2022-01-09
Figure 2 The structure of the Omicron mutant new coronavirus spike protein binding antibody JMB2002 .
-
On January 1, 2022, the new version of the medical insurance catalog will be officially implemented
Time of Update: 2022-01-09
Green Valley Pharmaceutical’s Alzheimer’s disease drug Phase 9 1 (mannite sodium) has been included in the medical insurance catalog with a 66% price reduction, and the latest price is 7.
-
Immunotherapy for small cell lung cancer: the PK of PD-1 and PD-L1
Time of Update: 2022-01-09
2019 and 2020, the US Food and Drug Administration (FDA) approved separately A teplizumab and of cutting Li You monoclonal joint first-line platinum-based chemotherapy etoposide and extensive stage small cell lung cancer (ES-SCLC) , This is the first new treatment approved in decades .
-
[Heavyweight] The first domestically produced Class 1 new anti-ED drug, AIRIS®, is on the market, and Yuekang Pharmaceutical has stepped up its innovation and upgrade
Time of Update: 2022-01-09
New product launches and multi-channel simultaneous efforts As a domestic patented new anti-ED drug, AIRIS® Aldenafil Citrate Tablets has the advantages of good patient experience, high safety, and low side effects compared with similar products on the market .
-
Annual inventory: top ten global M&A transactions in the biomedical field in 2021
Time of Update: 2022-01-09
Illumina acquires Grail for USD 8 billion In August 2021, gene sequencing giant Illumina announced the completion of the acquisition of blood testing company Grail for US$8 billion, officially entering the early cancer screening market .
